These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease. Holmes MV; Smith GD Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665 [TBL] [Abstract][Full Text] [Related]
4. What is 'LDL cholesterol'? Holmes MV; Ala-Korpela M Nat Rev Cardiol; 2019 Apr; 16(4):197-198. PubMed ID: 30700860 [No Abstract] [Full Text] [Related]
5. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein? Duriez P Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843 [No Abstract] [Full Text] [Related]
6. CETP Inhibition in CVD Prevention: an Actual Appraisal. Di Bartolo B; Takata K; Duong M; Nicholls SJ Curr Cardiol Rep; 2016 May; 18(5):43. PubMed ID: 27002619 [TBL] [Abstract][Full Text] [Related]
7. Unending saga of fighting cholesterol: Evacetrapib is another fallen warrior. Simko V Bratisl Lek Listy; 2016; 117(11):625-627. PubMed ID: 28125886 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?]. Murín J; Pernický M; Kiňová S Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865 [TBL] [Abstract][Full Text] [Related]
9. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia. Grundy SM Nat Rev Cardiol; 2016 Feb; 13(2):74-5. PubMed ID: 26763537 [No Abstract] [Full Text] [Related]
11. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both. Nicholls SJ Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215 [TBL] [Abstract][Full Text] [Related]
12. [Optimal cholesterol levels in patients in real-life. A systematic review]. Escobar C; Barrios V; Pérez de Isla L Semergen; 2018; 44(1):42-49. PubMed ID: 29153337 [TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia. Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356 [TBL] [Abstract][Full Text] [Related]
17. Future of cholesteryl ester transfer protein inhibitors. Rader DJ; deGoma EM Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575 [TBL] [Abstract][Full Text] [Related]
18. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430 [TBL] [Abstract][Full Text] [Related]
19. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Bajnok L Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322 [TBL] [Abstract][Full Text] [Related]